Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer

Heidi Fettke, Edmond M. Kwan, Patricia Bukczynska, Nicole Ng, Tu Nguyen-Dumont, Melissa C. Southey, Ian D. Davis, Andrew Mant, Phillip Parente, Carmel Pezaro, Christine Hauser, Arun A. Azad

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


A higher total cell-free DNA (cfDNA) level is a poor prognosticator in advanced prostate cancer patients receiving novel hormonal therapies. Additionally, an early on-treatment rise in cfDNA levels predicts for better outcomes. Therefore, total cfDNA concentration may assist in prognostication and predicting treatment outcome.

Original languageEnglish
Number of pages5
JournalEuropean Urology Focus
Publication statusAccepted/In press - 1 Jan 2020


  • Abiraterone
  • Androgen receptor pathway inhibitor
  • Biomarker
  • Castrate resistant
  • Cell-free DNA
  • Enzalutamide
  • Liquid biopsy
  • Prostate cancer

Cite this